Back

Therapeutic potential of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).

2 May 2017 (10:54 - 11:00)
Organised by:
Congress Presentation Part of: Moderated Poster session 6 - Therapy Pulmonary hypertension HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Doctor Tilmann Kramer

Cologne University Hospital - Heart Center, Cologne (Germany)

9 More presentations in this session

Presentation thumbnail
Granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the RIGENERA trial): 10 years follow-up- FINAL RESULTS
Doctor D. D'Amario (Novara, IT)
Abstract
Presentation thumbnail
Feasibility and benefit of neurohumoral blocker uptitration following cardiac resynchronization therapy
Doctor P. Martens (Genk, BE)
Abstract Slides
Presentation thumbnail
Relation of biological and functional LV remodeling to obstruction in hypertrophic cardiomyopathy. A rest and exercise echocardiographic study with longitudinal strain measurement
Professor J. Trochu (Nantes, FR)
Abstract
Presentation thumbnail
Early phase 99Tc-HMDP scintigraphy: a rapid and reliable technique for the diagnosis and typing of cardiac amyloidosis
Professor T. Damy (Creteil, FR)
Abstract
Presentation thumbnail
Less invasive ventricular reshaping provides sustained reduction of heart failure symptoms
Doctor M. Biffi (Bologna, IT)
Abstract

Access the full session

Session thumbnail
Moderated Poster session 6 - Therapy

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

2 May 2017 10:54 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources